Skip to main content
Top
Published in: Clinical and Experimental Medicine 2/2011

Open Access 01-06-2011 | Original Article

Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer

Authors: Marta Łukaszewicz-Zając, Barbara Mroczko, Mariusz Gryko, Bogusław Kędra, Maciej Szmitkowski

Published in: Clinical and Experimental Medicine | Issue 2/2011

Login to get access

Abstract

Gastric cancer (GC) is a second most common cause of cancer-related death and represents an inflammation-driven malignancy. It has been suggested that interleukin 6 (IL-6) and C-reactive protein (CRP) play a potential role in the growth and progression of GC. The aim of the present study was to compare clinical significance of IL-6 and CRP with classic tumor markers—carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) in GC patients. The study included 92 patients with GC and 70 healthy subjects. The serum concentrations of IL-6, CEA and CA 19-9 were determined using immunoenzyme assays, whereas CRP using immunoturbidimetric method. We defined the diagnostic criteria and prognostic value for proteins tested. In GC patients, the serum concentrations of all the proteins tested were significantly higher than in healthy subjects. The IL-6, CEA and CA 19-9 levels correlated with nodal metastases, while CRP with tumor stage, gastric wall invasion, presence of nodal and distant metastases. Diagnostic sensitivity of IL-6 was higher (85%) than those of other markers (CRP 66%, CA 19-9 34%, CEA 22%) and increased in combined use with CRP or CEA (88%). The area under ROC curve for IL-6 was larger than those of CRP and classic tumor markers (CEA and CA 19-9). None of the proteins tested was independent prognostic factor for the survival of GC patients. Our findings indicate better usefulness of serum proinflammatory proteins—IL-6 and CRP than classic tumor markers—CEA and CA 19-9 in the diagnosis of GC.
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRef
3.
go back to reference Ilhan N, Ilhan Y, Akbulut H, Kucuksu M (2004) C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 10:1115–1120PubMed Ilhan N, Ilhan Y, Akbulut H, Kucuksu M (2004) C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 10:1115–1120PubMed
4.
go back to reference Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121:2373–2380PubMedCrossRef Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121:2373–2380PubMedCrossRef
5.
go back to reference Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim HJ (2009) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9:155PubMedCrossRef Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim HJ (2009) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9:155PubMedCrossRef
6.
go back to reference Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, Tanaka S, Ohmoto Y, Chayama K (2005) Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res 25:709–713PubMed Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, Tanaka S, Ohmoto Y, Chayama K (2005) Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res 25:709–713PubMed
7.
go back to reference Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P’eng FK, Chi CW (1996) Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91:1417–1422PubMed Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P’eng FK, Chi CW (1996) Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91:1417–1422PubMed
8.
go back to reference Heikkilä K, Ebrahim S, Lawlor DA (2008) Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 44:937–945PubMedCrossRef Heikkilä K, Ebrahim S, Lawlor DA (2008) Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 44:937–945PubMedCrossRef
9.
go back to reference Wang CS, Sun CF (2009) C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 32:471–482PubMed Wang CS, Sun CF (2009) C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 32:471–482PubMed
10.
go back to reference Matsuo K, Oka M, Murase K, Soda H, Isomoto H, Takeshima F, Mizuta Y, Murata I, Kohno S (2003) Expression of interleukin 6 and its receptor in human gastric and colorectal cancers. J Int Med Res 31:69–75PubMed Matsuo K, Oka M, Murase K, Soda H, Isomoto H, Takeshima F, Mizuta Y, Murata I, Kohno S (2003) Expression of interleukin 6 and its receptor in human gastric and colorectal cancers. J Int Med Res 31:69–75PubMed
11.
go back to reference Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML, Lin JT (2002) Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 17:1165–1169PubMedCrossRef Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML, Lin JT (2002) Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 17:1165–1169PubMedCrossRef
12.
go back to reference Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM, Kuo ML (2007) IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 120:2600–2608PubMedCrossRef Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM, Kuo ML (2007) IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int J Cancer 120:2600–2608PubMedCrossRef
13.
go back to reference Ito R, Yasui W, Kuniyasu H, Yokozaki H, Tahara E (1987) Expression of interleukin-6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn J Cancer Res 88:953–958 Ito R, Yasui W, Kuniyasu H, Yokozaki H, Tahara E (1987) Expression of interleukin-6 and its effect on the cell growth of gastric carcinoma cell lines. Jpn J Cancer Res 88:953–958
14.
go back to reference Lee SA, Choi SR, Jang JS, Lee JH, Roh MH, Kim SO, Kim MC, Kim SJ, Jeong JS (2010) Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci 55:1955–1963PubMedCrossRef Lee SA, Choi SR, Jang JS, Lee JH, Roh MH, Kim SO, Kim MC, Kim SJ, Jeong JS (2010) Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. Dig Dis Sci 55:1955–1963PubMedCrossRef
15.
go back to reference Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, Huang YJ, Wu MS (2008) Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 14:428–434PubMedCrossRef Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, Huang YJ, Wu MS (2008) Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res 14:428–434PubMedCrossRef
16.
go back to reference Kallio R, Surcel HM, Bloigu A, Syrjälä H (2000) C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 36:889–894PubMedCrossRef Kallio R, Surcel HM, Bloigu A, Syrjälä H (2000) C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 36:889–894PubMedCrossRef
17.
go back to reference Groblewska M, Mroczko B, Wereszczyńska-Siemiątkowska U, Kędra B, Łukaszewicz M, Baniukiewicz A, Szmitkowski M (2008) Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46:1423–1428PubMedCrossRef Groblewska M, Mroczko B, Wereszczyńska-Siemiątkowska U, Kędra B, Łukaszewicz M, Baniukiewicz A, Szmitkowski M (2008) Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46:1423–1428PubMedCrossRef
18.
go back to reference Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, Onitsuka T (2007) Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 27:3001–3004PubMed Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, Onitsuka T (2007) Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 27:3001–3004PubMed
19.
go back to reference Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S (2009) Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12:95–100PubMedCrossRef Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S (2009) Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12:95–100PubMedCrossRef
20.
go back to reference Jang JS, Choi SR, Han SY, Roh MH, Lee JH, Lee SW, Jeung JS, Kim MC, Son YK, Baek YH (2009) Predictive significance of serum IL-6, VEGF, and CRP in gastric adenoma and mucosal carcinoma before endoscopic submucosal dissection. Korean J Gastroenterol 54:99–107PubMedCrossRef Jang JS, Choi SR, Han SY, Roh MH, Lee JH, Lee SW, Jeung JS, Kim MC, Son YK, Baek YH (2009) Predictive significance of serum IL-6, VEGF, and CRP in gastric adenoma and mucosal carcinoma before endoscopic submucosal dissection. Korean J Gastroenterol 54:99–107PubMedCrossRef
21.
go back to reference Jass JR, Sobin LH (1989) WHO international histological classification of tumors. Springer-Verlag, Histological typing of intestinal tumors. New York Jass JR, Sobin LH (1989) WHO international histological classification of tumors. Springer-Verlag, Histological typing of intestinal tumors. New York
22.
23.
go back to reference Shim KN, Jung SA, Joo YH, Yoo K (2007) Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol 42:120–128PubMedCrossRef Shim KN, Jung SA, Joo YH, Yoo K (2007) Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol 42:120–128PubMedCrossRef
24.
go back to reference Mroczko B, Groblewska M, Łukaszewicz-Zajac M, Bandurski R, Kedra B, Szmitkowski M (2009) Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin Chem Lab Med 47:1133–1139PubMedCrossRef Mroczko B, Groblewska M, Łukaszewicz-Zajac M, Bandurski R, Kedra B, Szmitkowski M (2009) Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clin Chem Lab Med 47:1133–1139PubMedCrossRef
25.
go back to reference Mroczko B, Wereszczynska-Siemiatkowska U, Groblewska M, Lukaszewicz M, Szmitkowski M, Gryko M, Kedra B (2006) The diagnostic value of hematopoietic cytokines measurement in the sera of gastric cancer and gastric ulcer patients. Clin Chim Acta 374:165–167PubMedCrossRef Mroczko B, Wereszczynska-Siemiatkowska U, Groblewska M, Lukaszewicz M, Szmitkowski M, Gryko M, Kedra B (2006) The diagnostic value of hematopoietic cytokines measurement in the sera of gastric cancer and gastric ulcer patients. Clin Chim Acta 374:165–167PubMedCrossRef
26.
go back to reference Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y (2006) Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 12:4473–4477PubMed Thong-Ngam D, Tangkijvanich P, Lerknimitr R, Mahachai V, Theamboonlers A, Poovorawan Y (2006) Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol 12:4473–4477PubMed
27.
go back to reference Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S, Aoki T (2005) Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8:124–131PubMedCrossRef Ashizawa T, Okada R, Suzuki Y, Takagi M, Yamazaki T, Sumi T, Aoki T, Ohnuma S, Aoki T (2005) Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8:124–131PubMedCrossRef
28.
go back to reference Mroczko B, Groblewska M, Gryko M, Kędra B, Szmitkowski M (2010) Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 24:265–271CrossRef Mroczko B, Groblewska M, Gryko M, Kędra B, Szmitkowski M (2010) Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 24:265–271CrossRef
Metadata
Title
Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer
Authors
Marta Łukaszewicz-Zając
Barbara Mroczko
Mariusz Gryko
Bogusław Kędra
Maciej Szmitkowski
Publication date
01-06-2011
Publisher
Springer Milan
Published in
Clinical and Experimental Medicine / Issue 2/2011
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-010-0114-5

Other articles of this Issue 2/2011

Clinical and Experimental Medicine 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.